Following FMT intervention in melanoma patients with poor response to anti‐PD‐1 therapy, studies identified significant changes in their immune microenvironment, primarily manifested as upregulated activation levels of tumor‐infiltrating CD8+ T cells, thereby partially counteracting the immunosuppressive state within the TME. This evidence concerns the gene PDCD1 and melanoma.